https://www.nccn.org/
Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P,
Panteli K, Repousis P, Mitsouli-Mentzikof C. Dexamethasone,
cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or
refractory multiple myeloma patients. J BUON. 2007 Jan-Mar;12(1):41-4.
PMID: 17436400.
Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, Shaw BE,
Saso RM, Dines S, Morgan GJ. Survival and outcome of blastoid variant
myeloma following treatment with the novel thalidomide containing
regime DT-PACE. Eur J Haematol. 2008 Dec;81(6):432-6. doi:
10.1111/j.1600-0609.2008.01131.x. Epub 2008 Aug 6. PMID: 18691254.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM,
Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World
Health Organization classification of myeloid neoplasms and acute
leukemia. Blood. 2016 May 19;127(20):2391-405. doi:
10.1182/blood-2016-03-643544. Epub 2016 Apr 11. PMID: 27069254.
Клинический протокол МЗ РК «Коронавирусная инфекция - COVID-19», 10-я
редакция с изменениями от 15.07.2020г
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2
infection: a nationwide analysis in China. Lancet Oncol .
2020;21(3):335-337. DOI:10.1016/S1470-2045(20)30096-6